Pharmacokinetics Of CP-690,550 In Pediatric Patients With Juvenile Idiopathic Arthritis (JIA)

Exclusion Criteria

• •1. Systemic JIA, persistent oligoarthritis, undifferentiated arthritis.
• •2. Current or recent history of uncontrolled clinically significant renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, cardiac, or neurological disease.
• •3. History of any other rheumatic autoimmune disease.
• •4. Infections:
• •1. Latent or active TB or any history of previous TB.
• •2. Chronic infections.
• •3. Any infection requiring hospitalization, parenteral antimicrobial therapy or judged to be opportunistic by the investigator within the 6 months prior to the first dose of study drug.
• •4. Any treated infections within 2 weeks of Baseline visit.
• •5. A subject known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C virus.
• •6. History of infected joint prosthesis with prosthesis still in situ.
• •5. History of recurrent (more than one episode) herpes zoster or disseminated (a single episode) herpes zoster or disseminated (a single episode) herpes simplex.
• •6. The biologic agents and DMARDs are disallowed at any time during this study. If a subject needs to be treated with one of these agents, the subject should be discontinued from the study.
• •7. Subjects who have been vaccinated with live or attenuated vaccines within the 6 weeks prior to the first dose of study medication or is to be vaccinated with these vaccines at any time during treatment or within 6 weeks following discontinuation of study drug.
• •8. Subjects with a malignancy or with a history of malignancy with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin or cervical carcinoma in situ.